BiotechTube
Serpin Pharma

Serpin Pharma

Charlottesville, United States· Est.
serpinpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Serpin Pharma is a private, pre-revenue biotech developing SP16, a first-in-class peptide therapeutic targeting the LRP1 receptor to resolve harmful inflammation. With a robust IP estate covering composition of matter, the company is advancing SP16 through pre-clinical and clinical trials for multiple inflammatory indications. The leadership team combines scientific, clinical, and business expertise, positioning the company to address a massive anti-inflammatory therapeutics market projected to exceed $130 billion.

Inflammatory DiseasesCardiologyImmunology

Technology Platform

Engineered peptide platform based on fragments of natural SERPIN proteins, modified for enhanced binding to the LRP1 receptor to restore inflammatory homeostasis.

Funding History

2
Total raised:$3.5M
Seed$3M
Grant$500K

Opportunities

The global anti-inflammatory market is massive and growing, projected to exceed $130 billion.
SP16's novel mechanism of restoring immune balance, rather than broad suppression, addresses a key unmet need and could be applied across a wide range of acute and chronic diseases.
Strong composition-of-matter IP provides long-term exclusivity potential.

Risk Factors

High clinical development risk as the novel peptide moves from pre-clinical models into human trials.
The company is pre-revenue and privately funded, making it dependent on future capital raises.
It faces significant competition from established and emerging anti-inflammatory therapies.

Competitive Landscape

Serpin Pharma competes in the crowded anti-inflammatory drug market against large pharmaceutical companies with biologic TNF-alpha inhibitors, IL inhibitors, JAK inhibitors, and steroids. Its differentiation lies in a first-in-class peptide targeting the LRP1 pathway to restore homeostasis, a mechanism distinct from current standards of care. Success depends on demonstrating superior efficacy or safety profiles.

More companies in Biologics / Biosimilars →More companies in United States →